|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1159208655 |
| 003 |
OCoLC |
| 005 |
20231120010458.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
200622s2020 enk o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d EBLCP
|d OCLCF
|d OCLCQ
|d OCLCO
|d SFB
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 1163521108
|
| 020 |
|
|
|a 9780128209271
|q (electronic bk.)
|
| 020 |
|
|
|a 0128209275
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128204993
|
| 020 |
|
|
|z 0128204990
|
| 035 |
|
|
|a (OCoLC)1159208655
|z (OCoLC)1163521108
|
| 050 |
|
4 |
|a RC271.C35
|
| 082 |
0 |
4 |
|a 616.994061
|2 23
|
| 245 |
0 |
0 |
|a Camptothecin and camptothecin producing plants :
|b botany, chemistry, anticancer activity and biotechnology /
|c T. Pullaiah, P.B. Raghavendra, S. Karuppusamy, V. Raveendran, M. Anuradha.
|
| 260 |
|
|
|a London :
|b Academic Press,
|c 2020.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Includes index.
|
| 505 |
0 |
|
|a Front Cover -- Camptothecin and Camptothecin Producing Plants -- Copyright Page -- Contents -- Preface -- Abbreviations -- 1 Cancer biology and other disorders: beneficial role of camptothecin and novel derivatives -- 1.1 Introduction -- 1.2 The principles underlying transformation of normal cells into tumor -- 1.2.1 Self-sufficiency in growth signals -- 1.2.2 Insensitivity to antigrowth signals -- 1.2.3 Evading apoptosis -- 1.2.4 Limitless Replicative potential -- 1.2.5 Sustained angiogenesis -- 1.2.6 Tissue invasion and metastasis -- 1.3 Nuclear transcription factor kappa B
|
| 505 |
8 |
|
|a 1.6.1 Deregulation of the apoptotic machinery -- 1.6.1.1 Expression of antiapoptotic proteins -- 1.6.1.2 Inactivation of proapoptotic genes -- 1.6.2 Drug influx and efflux -- 1.6.3 Drug inactivation -- 1.6.4 Drug targets -- 1.6.5 Alterations of the p53 pathway -- 1.6.6 DNA damage repair -- 1.6.7 Alterations in the survival signaling -- 1.6.8 Cell cycle events in context to antitumor agents -- 1.7 Strategy to overcome chemoresistance -- 1.7.1 Combination therapy -- 1.8 Camptothecin -- 1.8.1 Camptothecin and related derivatives-biological activity -- 1.8.1.1 Antitumor activity
|
| 505 |
8 |
|
|a 1.8.1.2 Antiviral activity -- 1.8.1.3 Pesticidal activity -- 1.8.1.4 Antiparasitic activity -- 1.8.1.5 Antipsoriasis activity -- 1.8.1.6 Antifungal/antimicrobial activity -- 1.8.1.7 Hypoxia-inducible factor inhibitory activity -- 1.9 Conclusions -- References -- 2 Camptothecin: chemistry, biosynthesis, analogs, and chemical synthesis -- 2.1 Introduction -- 2.2 Chemistry of camptothecin -- 2.3 A historical account on the discovery of camptothecin -- 2.4 Plant sources of camptothecin -- 2.5 Factors affecting camptothecin production in plants -- 2.5.1 Nothopodytes
|
| 505 |
8 |
|
|a 2.5.1.1 Geographical factors affecting camptothecin synthesis -- 2.5.1.2 Seasons -- 2.5.1.3 Plant parts -- 2.5.2 Ophiorrhiza -- 2.6 Camptothecin from endophytes -- 2.7 Biosynthetic pathway -- 2.8 Extraction of camptothecin -- 2.9 Clinically useful derivatives of camptothecin -- 2.9.1 Topotecan (hycamtin) -- 2.9.2 Irinotcan -- 2.9.3 Etirinotecan pegol, a conjugate of irinotecan -- 2.10 Analogs of camptothecin under clinical investigation -- 2.10.1 Rubitecan -- 2.10.2 Exatecan -- 2.10.3 FL118, a novel structurally similar analog of camptothecin -- 2.10.4 Gimatecan -- 2.10.5 Morpholinocamptothecin
|
| 650 |
|
0 |
|a Camptothecin.
|
| 650 |
|
2 |
|a Camptothecin
|0 (DNLM)D002166
|
| 650 |
|
6 |
|a Camptoth�ecine.
|0 (CaQQLa)201-0265951
|
| 650 |
|
7 |
|a Camptothecin
|2 fast
|0 (OCoLC)fst00845002
|
| 700 |
1 |
|
|a Pullaiah, T.
|
| 776 |
0 |
8 |
|i Print version:
|t Camptothecin and camptothecin producing plants.
|d London : Academic Press, 2020
|z 0128204990
|z 9780128204993
|w (OCoLC)1147258962
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128204993
|z Texto completo
|
